Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 7/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 4/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1260528 | 0.86 | USP30 (0.33) | JAK1USP30 | |
| SCHEMBL1260709 | 0.85 | HSD11B1 (0.35) | USP30 | |
| SCHEMBL704571 | 0.83 | ABCB1 (0.41) | PRMT5JAK2JAK1USP30 | |
| SCHEMBL27223224 | 0.83 | ABCB1 (0.41) | PRMT5JAK2JAK1USP30 | |
| SCHEMBL23043429 | 0.83 | ABCB1 (0.41) | PRMT5JAK2JAK1USP30 | |
| SCHEMBL16106798 | 0.80 | PRMT5 (0.35) | PRMT5GRIN2B | |
| SCHEMBL2439748 | 0.79 | USP30 (0.47) | USP30 | |
| SCHEMBL10196271 | 0.78 | PRMT5 (0.52) | PRMT5 | |
| SCHEMBL1260700 | 0.77 | MCL1 (0.47) | PRMT5GHSR | |
| SCHEMBL12093209 | 0.77 | GPR119 (0.50) | PRMT5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046161-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046161-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, GTF3C3, CTSC | PRMT5 2225/4885GRIN2B 4806/4885GHSR 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.